Platinum-Resistant Ovarian Cancer
A Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen (innovaTV 208)
Women with platinum resistant ovarian cancer are asked to participate in a research study being conducted by Icahn School of Medicine at Mount Sinai.
You may be eligible to participate in this study if you:
- Are a female at least 18 years of age or older
- Have histologic documentation of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
You may not participate in this study if you:
- Have primary platinum-refractory disease, defined as disease progression within 2 months of completion of first line platinum-based therapy
- Have had gastrointestinal obstruction within the past 6 months or who currently require parenteral nutrition
- Have known past or current coagulation defects leading to an increased risk of bleeding
- Have clinically significant cardiac disease
- Have active ocular surface disease
- Have ongoing, acute, or chronic inflammatory skin disease
- Have uncontrolled tumor-related pain
- Have Inflammatory lung disease requiring chronic medical therapy
- Have Grade 3 or higher pulmonary disease unrelated to underlying malignancy
- Have Grade >1 peripheral neuropathy
- Have inflammatory bowel disease including Crohn’s disease and ulcerative colitis
- Are pregnant, breastfeeding or plan to become pregnant
Contact Information
Martina Kracikova, PhD, Study Coordinator
One Gustave L. Levy Place, Box 1170
New York, New York 10029
Phone: 212 824 7859
Email: martina.kracikova@mssm.edu